The Complete Success in Refractory Mooren's Ulcer Treated with Infliximab

Ocul Immunol Inflamm. 2022 Jul 13;1-7. doi: 10.1080/09273948.2022.2091615. Online ahead of print.


Purpose: To describe the management and outcome of two extremely rare and painful cases of Mooren's ulcer, an idiopathic peripheral autoimmune-associated ulcerative corneal disease.

Methods: Case report with literature review on the management of ocular inflammation in Mooren's ulcer.

Results: A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren's ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups.

Conclusion: This case report highlights how infliximab can be effective in cases with Mooren's ulcer refractory to conventional therapies.

Keywords: Anti-tumor necrosis factor alpha; Mooren’s ulcer; immunosuppresion; infliximab; peripheral ulcerative keratitits.